A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Tóm tắt tin
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Theo dõi tin mới từ các nhà xuất bản đáng tin cậy cùng phần tóm tắt ngắn. Mở liên kết nguồn gốc để xem chi tiết.